Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeiGene's financial position is robust, closing 2024 with US$2.6 billion in cash, which provides a solid foundation for ongoing operations and potential expansions. The company experienced significant growth in its core drug, Brukinsa, achieving a 105% year-over-year increase in sales to US$2.6 billion, indicating strong market demand and momentum. Additionally, BeiGene's other product, Tevimbra, reported a 16% increase in sales, further demonstrating the company's competitive positioning in the oncology market and enhancing its future revenue projections.

Bears say

BeiGene is experiencing a concerning financial trajectory, as evidenced by a significant drop in cash flow from financing operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter of 2024 due to increased receivables and inventory. The company recorded a net loss of US$645 million, although this represents a narrowing of 27% year-over-year. Projections indicate minimal revenue growth in mature markets for 2025, combined with downward revisions to sales estimates for key products, reflecting significant potential downside risks for the stock.

BeiGene Ltd (ONC) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 6 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jun 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $328.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $328.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.